<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336699">
  <stage>Registered</stage>
  <submitdate>24/03/2011</submitdate>
  <approvaldate>24/03/2011</approvaldate>
  <actrnumber>ACTRN12611000316909</actrnumber>
  <trial_identification>
    <studytitle>The effect of proton pump inhibitor on mycophenolic acid absorption in kidney and liver transplant recipients</studytitle>
    <scientifictitle>A prospective, double-blind placebo-controlled multicentre trial to assess mycophenolic acid area under curve following Mycophenolate Mofetil and Enteric-coated Mycophenolic Acid in the presence and absence of the proton-pump inhibitor Pantoprazole in kidney and liver transplant recipients</scientifictitle>
    <utrn />
    <trialacronym>Interaction of the Proton Pump Inhibitor (PPI) Pantoprazole on MycoPhenolic ACid (MPA) exposure In Kidney And Liver Transplant Recipients (IMPACT Study)</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Drug interaction</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Pantoprazole 40mg oral tablet once daily for 7 days.  There will be a 1-week washout period between treatments.</interventions>
    <comparator>Placebo (identical in taste and appearance with no active ingredient) 1 tablet once daily for 7 days. There will be a 1-week washout period between treatments.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Dose normalised area under the curve (AUC) for mycophenolic acid (MPA) and MPA-ether glucuronide (MPA-Ge) will be determined using validated assay</outcome>
      <timepoint>Days 7 and 21</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Transplant graft outcomes (clinical assessments, blood and urine test)</outcome>
      <timepoint>Days 7 and 21</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma calcineurin-inhibitor levels (blood test)</outcome>
      <timepoint>Days 7 and 21</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma pantoprazole levels (blood test)</outcome>
      <timepoint>Days 7 and 21</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria:
1.	Males and females &gt;18 years.
2.	Kidney and liver transplant recipients of deceased-donor organs or for renal only, living donor organs. Recipients must be at least 6 months post-transplant. 
3.	Recipients who are willing to change to pantoprazole (from other proton-pump inhibitor or H2-antagonist) or willing to start pantoprazole if not already on this drug.
4.	Maintained on either cyclosporine or tacrolimus.
5.	Capable of giving written informed consent and adhering to the study schedule.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion Criteria:
1.	Recipients who are unwilling to change to pantoprazole (from other proton-pump inhibitor or H2-antagonist) or unwilling to start pantoprazole if not already on this. 
2.	Patients maintained on everolimus, sirolimus or other non-calcineurin inhibitor except corticosteroids.
3.	Recent change (&lt;2 weeks) in dose of mycophenolate mofetil or enteric coated-mycophenolic sodium (EC-MPS).
4.	Recent substantial change (&gt;50% change in dosage within 2 weeks prior to inclusion) in dose of calcineurin-inhibitor (CNI).
5.	Recent acute rejection requiring methylprednisolone within 1 month prior to inclusion.
6.	Change in dose of corticosteroids (prednisolone) within 2 weeks prior to inclusion.
7.	MDRD derived estimated glomerular filtration rate (eGFR) &lt;30mL/min or alanine amino-transaminase (ALT) &gt;3x upper limit of normal (ULN) or aspartate amino-transferase (AST) &gt;3xULN or bilirubin &gt;2xULN.
8.	Plan change in dosing of MMF or EC-MPS or CNI during study period.
9.	Significant peptic ulcer disease or ulcerative oesophagitis where withdrawal of current acid suppression therapy is not clinically appropriate.
10.	Concurrent use of magnesium and aluminium antacid or cholestyramine.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The authorized person(s) and/or research staff will receive a set of treatment allocation cards (separate cards for kidney and liver transplant recipients) with sequential randomization numbers on which the treatment group information is covered by a label or sealed within an envelope. Each number will correspond to 2 packets of study medications clearly labelled as ‘Packet 1’ or ‘Packet 2’.</concealment>
    <sequence>Simple randomisation by coin-tossing</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/06/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>42</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>6009</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Health Department of Western Australia</primarysponsorname>
    <primarysponsoraddress>Department of Health 
189 Royal Street 
East Perth WA 6004</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Novartis Pharmaceuticals Australia Pty Limited</fundingname>
      <fundingaddress>54 Waterloo Road
North Ryde NSW 2113</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>Royal Adelaide Hospital</othercollaboratorname>
      <othercollaboratoraddress>PO Box 287
Rundle Mall
South Australia 5000</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To determine the effect of gastric acid suppression (using the proton pump inhibitor [PPI] pantoprazole) on the pharmacokinetics of mycophenolic acid (MPA) in kidney and liver transplant recipients maintained on either mycophenolate mofetil [MMF] or enteric-coated mycophenolate sodium [EC-MPS]. The following outcomes will be assessed:
a.	MPA area under curve (AUC).
b.	Clinical outcomes including rejection, graft function and proteinuria.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Hospital Group</ethicname>
      <ethicaddress>Hospital Avenue,
NEDLANDS WA 6009</ethicaddress>
      <ethicapprovaldate />
      <hrec>2011-004</hrec>
      <ethicsubmitdate>1/02/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress>PO Box 287
Rundle Mall
South Australia 5000</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>23/03/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Wai Lim</name>
      <address>Department of Renal Medicine
Sir Charles Gairdner Hospital
Hospital Avenue,
NEDLANDS WA 6009</address>
      <phone>+61 8 93462799</phone>
      <fax>+61 8 93463942</fax>
      <email>wai.lim@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Wai Lim</name>
      <address>Department of Renal Medicine
Sir Charles Gairdner Hospital
Hospital Avenue,
NEDLANDS WA 6009</address>
      <phone>+61 8 93462799</phone>
      <fax>+61 8 93463942</fax>
      <email>wai.lim@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Wai Lim</name>
      <address>Department of Renal Medicine
Sir Charles Gairdner Hospital
Hospital Avenue,
NEDLANDS WA 6009</address>
      <phone>+61 8 93462799</phone>
      <fax>+61 8 93463942</fax>
      <email>wai.lim@health.wa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>